TNF and posterior uveitis: Given the persistence of bilateral posterior uveitis despite the control of systemic inflammation, we chose tumor necrosis factor inhibitor (anti-TNF) therapy because it has already proven to be beneficial in non-infectious uveitis [11], [12].